nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

26.11.2019 | Original Article

Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models

verfasst von: Benjamin B. Kasten, Ke Jiang, Denzel Cole, Aditi Jani, Neha Udayakumar, G. Yancey Gillespie, Guolan Lu, Tingting Dai, Eben L. Rosenthal, James M. Markert, Jianghong Rao, Jason M. Warram

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

There is a clinical need for agents that target glioma cells for non-invasive and intraoperative imaging to guide therapeutic intervention and improve the prognosis of glioma. Matrix metalloproteinase (MMP)-14 is overexpressed in glioma with negligible expression in normal brain, presenting MMP-14 as an attractive biomarker for imaging glioma. In this study, we designed a peptide probe containing a near-infrared fluorescence (NIRF) dye/quencher pair, a positron emission tomography (PET) radionuclide, and a moiety with high affinity to MMP-14. This novel substrate-binding peptide allows dual modality imaging of glioma only after cleavage by MMP-14 to activate the quenched NIRF signal, enhancing probe specificity and imaging contrast.

Methods

MMP-14 expression and activity in human glioma tissues and cells were measured in vitro by immunofluorescence and gel zymography. Cleavage of the novel substrate and substrate-binding peptides by glioma cells in vitro and glioma xenograft tumors in vivo was determined by NIRF imaging. Biodistribution of the radiolabeled MMP-14-binding peptide or substrate-binding peptide was determined in mice bearing orthotopic patient-derived xenograft (PDX) glioma tumors by PET imaging.

Results

Glioma cells with MMP-14 activity showed activation and retention of NIRF signal from the cleaved peptides. Resected mouse brains with PDX glioma tumors showed tumor-to-background NIRF ratios of 7.6–11.1 at 4 h after i.v. injection of the peptides. PET/CT images showed localization of activity in orthotopic PDX tumors after i.v. injection of ⁶⁸Ga-binding peptide or ⁶⁴Cu-substrate-binding peptide; uptake of the radiolabeled peptides in tumors was significantly reduced (p < 0.05) by blocking with the non-labeled-binding peptide. PET and NIRF signals correlated linearly in the orthotopic PDX tumors. Immunohistochemistry showed co-localization of MMP-14 expression and NIRF signal in the resected tumors.

Conclusions

The novel MMP-14 substrate-binding peptide enabled PET/NIRF imaging of glioma models in mice, warranting future image-guided resection studies with the probe in preclinical glioma models.

Nur mit Berechtigung zugänglich

Delgado-López PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016;18(11):1062–71.PubMedCrossRef

Orringer D, Lau D, Khatri S, Grettel J. Zamora-Berridi; Kathy Zhang; Chris Wu; Neeraj Chaudhary; Oren Sagher, Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg. 2012;117(5):851–9.PubMedCrossRef

Li YM, Suki D, Hess K, Sawaya R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg. 2016;124(4):977–88.PubMedCrossRef

Shiomi T, Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev. 2003;22(2):145–52.PubMedCrossRef

Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67.PubMedPubMedCentralCrossRef

Beliën ATJ, Paganetti PA, Schwab ME. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J Cell Biol. 1999;144(2):373–84.PubMedPubMedCentralCrossRef

Fillmore HL, VanMeter TE, Broaddus WC. Membrane-type matrix metalloproteinases (MT-MMP)s: expression and function during glioma invasion. J Neuro-Oncol. 2001;53(2):187–202.CrossRef

Nakada M, Nakamura H, Ikeda E, Fujimoto N, Yamashita J, Sato H, et al. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol. 1999;154(2):417–28.PubMedPubMedCentralCrossRef

Wang L, Yuan J, Tu Y, Mao X, He S, Fu G, et al. Co-expression of MMP-14 and MMP-19 predicts poor survival in human glioma. Clin Transl Oncol. 2013;15(2):139–45.PubMedCrossRef

10.

Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, Muzik H, et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer. 1999;79(11-12):1828–35.PubMedPubMedCentralCrossRef

11.

Yamamoto M, Mohanam S, Sawaya R, Fuller GN, Seiki M, Sato H, et al. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res. 1996;56(2):384–92.PubMed

12.

Gu G, Gao X, Hu Q, Kang T, Liu Z, Jiang M, et al. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells. Biomaterials. 2013;34(21):5138–48.PubMedCrossRef

13.

de Lucas AG, Schuhmacher AJ, Oteo M, Romero E, Cámara JA, de Martino A, et al. Targeting MT1-MMP as an ImmunoPET-based strategy for imaging gliomas. PLoS One. 2016;11(7):e0158634.PubMedPubMedCentralCrossRef

14.

Shimizu Y, Temma T, Hara I, Makino A, Kondo N, Ozeki E, et al. In vivo imaging of membrane type-1 matrix metalloproteinase with a novel activatable near-infrared fluorescence probe. Cancer Sci. 2014;105(8):1056–62.PubMedPubMedCentralCrossRef

15.

Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response assessment in neuro-oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology. 2016;18(9):1199–208.PubMedPubMedCentralCrossRef

16.

Kondo A, Ishii H, Aoki S, Suzuki M, Nagasawa H, Kubota K, et al. Phase IIa clinical study of [¹⁸F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors. Ann Nucl Med. 2016;30(9):608–18.PubMedCrossRef

17.

Filss CP, Galldiks N, Stoffels G, Sabel M, Wittsack HJ, Turowski B, et al. Comparison of ¹⁸F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. J Nucl Med. 2014;55(4):540–5.PubMedCrossRef

18.

Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Galldiks N, et al. Prognostic impact of postoperative, pre-irradiation ¹⁸F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol. 2011;99(2):218–24.PubMedCrossRef

19.

la Fougère C, Suchorska B, Bartenstein P, Kreth F-W, Tonn J-C. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro-Oncology. 2011;13(8):806–19.PubMedPubMedCentralCrossRef

20.

Tsuyuguchi N, Takami T, Sunada I, Iwai Y, Yamanaka K, Tanaka K, et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery —In malignant glioma—. Ann Nucl Med. 2004;18(4):291–6.PubMedCrossRef

21.

Lodge MA, Holdhoff M, Leal JP, Bag AK, Nabors LB, Mintz A, et al. Repeatability of ¹⁸F-FLT PET in a multicenter study of patients with high-grade glioma. J Nucl Med. 2017;58(3):393–8.PubMedPubMedCentralCrossRef

22.

Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, et al. Biopsy validation of ¹⁸F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro-Oncology. 2013;15(8):1058–67.PubMedPubMedCentralCrossRef

23.

Bangiyev L, Rossi Espagnet MC, Young R, Shepherd T, Knopp E, Friedman K, et al. Adult brain tumor imaging: state of the art. Semin Roentgenol. 2014;49(1):39–52.PubMedCrossRef

24.

Díez Valle R, Tejada Solis S, Idoate Gastearena MA. García de Eulate, R.; Domínguez Echávarri, P.; Aristu Mendiroz, J., Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. J. Neurooncol.2011;102(1):105–13.CrossRef

25.

Schucht P, Beck J, Abu-Isa J, Andereggen L, Murek M, Seidel K, et al. Gross total resection rates in contemporary glioblastoma surgery: results of an institutional protocol combining 5-aminolevulinic acid intraoperative fluorescence imaging and brain mapping. Neurosurgery. 2012;71(5):927–36.PubMedCrossRef

26.

Stummer W, Stocker S, Wagner S, Stepp H, Fritsch C, Goetz C, et al. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery. 1998;42(3):518–25 discussion 525-6.PubMedCrossRef

27.

Tonn JC, Stummer W. Fluorescence-guided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls. Clin Neurosurg. 2008;55:20–6.PubMed

28.

FDA Briefing Information for the May 10, 2017 Meeting of the Medical Imaging Drugs Advisory Committee: NDA 208630 5-ALA (5-aminolevulinic acid HCl). https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/MedicalImagingDrugsAdvisoryCommittee/ucm557135.htm ().

29.

Liu JT, Meza D, Sanai N. Trends in fluorescence image-guided surgery for gliomas. Neurosurgery. 2014;75(1):61–71.PubMedPubMedCentralCrossRef

30.

Belykh E; Martirosyan NL; Yagmurlu K; Miller EJ; Eschbacher JM; Izadyyazdanabadi M; Bardonova LA; Byvaltsev VA; Nakaji P; Preul MC. Intraoperative fluorescence imaging for personalized brain tumor resection: current state and future directions. Front Surg.2016;3:(55).

31.

Zhang RR, Schroeder AB, Grudzinski JJ, Rosenthal EL, Warram JM, Pinchuk AN, et al. Beyond the margins: real-time detection of cancer using targeted fluorophores. Nat Rev Clin Oncol. 2017;14(6):347–64.PubMedPubMedCentralCrossRef

32.

Huang R, Vider J, Kovar JL, Olive DM, Mellinghoff IK, Mayer-Kuckuk P, et al. Integrin α_vβ₃-Targeted IRDye 800CW Near-infrared imaging of glioblastoma. Clin Cancer Res. 2012;18(20):5731–40.PubMedPubMedCentralCrossRef

33.

de Souza ALR, Marra K, Gunn J, Samkoe KS, Hoopes PJ, Feldwisch J, et al. Fluorescent affibody molecule administered in vivo at a microdose level labels EGFR expressing glioma tumor regions. Mol Imaging Biol. 2017;19(1):41–8.PubMedCrossRef

34.

Miller SE, Tummers WS, Teraphongphom N, van den Berg NS, Hasan A, Ertsey RD, et al. First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800. J Neuro-Oncol. 2018;139(1):135–43.CrossRef

35.

Cepeda MA, Evered CL, Pelling JJH, Damjanovski S. Inhibition of MT1-MMP proteolytic function and ERK1/2 signalling influences cell migration and invasion through changes in MMP-2 and MMP-9 levels. J Cell Commun Signal. 2017;11(2):167–79.PubMedPubMedCentralCrossRef

36.

Atkinson JM, Falconer RA, Edwards DR, Pennington CJ, Siller CS, Shnyder SD, et al. Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases. Cancer Res. 2010;70(17):6902–12.PubMedPubMedCentralCrossRef

37.

Ansari C, Tikhomirov GA, Hong SH, Falconer RA, Loadman PM, Gill JH, et al. Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. Small. 2014;10(3):566–75.PubMedCrossRef

38.

Mohanty S, Chen Z, Li K, Morais GR, Klockow J, Yerneni K, et al. A novel theranostic strategy for MMP-14-expressing glioblastomas impacts survival. Mol Cancer Ther. 2017;16(9):1909–21.PubMedPubMedCentralCrossRef

39.

Peng X, Chen H, Draney DR, Volcheck W, Schutz-Geschwender A, Olive DM. A nonfluorescent, broad-range quencher dye for Förster resonance energy transfer assays. Anal Biochem. 2009;388(2):220–8.PubMedCrossRef

40.

Simard B, Tomanek B, van Veggel FC, Abulrob A. Optimal dye-quencher pairs for the design of an "activatable" nanoprobe for optical imaging. Photochem Photobiol Sci. 2013;12(10):1824–9.PubMedCrossRef

41.

Zhu L, Wang H, Wang L, Wang Y, Jiang K, Li C, et al. High-affinity peptide against MT1-MMP for in vivo tumor imaging. J Control Release. 2011;150(3):248–55.PubMedPubMedCentralCrossRef

42.

Kondo N, Temma T, Shimizu Y, Ono M, Saji H. Radioiodinated peptidic imaging probes for in vivo detection of membrane type-1 matrix metalloproteinase in cancers. Biol Pharm Bull. 2015;38(9):1375–82.PubMedCrossRef

43.

Min K, Ji B, Zhao M, Ji T, Chen B, Fang X, et al. Development of a radiolabeled peptide-based probe targeting MT1-MMP for breast cancer detection. PLoS One. 2015;10(10):e0139471.PubMedPubMedCentralCrossRef

44.

Gill JH, Loadman PM, Shnyder SD, Cooper P, Atkinson JM, Ribeiro Morais G, et al. Tumor-targeted prodrug ICT2588 demonstrates therapeutic activity against solid tumors and reduced potential for cardiovascular toxicity. Mol Pharm. 2014;11(4):1294–300.PubMedCrossRef

45.

Snyman C, Niesler CU. MMP-14 in skeletal muscle repair. J Muscle Res Cell Motil. 2015;36(3):215–25.PubMedCrossRef

46.

Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-Oncology. 2005;7(2):164–76.PubMedPubMedCentralCrossRef

47.

Oliva CR, Nozell SE, Diers A, McClugage SG 3rd, Sarkaria JN, Markert JM, et al. Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. J Biol Chem. 2010;285(51):39759–67.PubMedPubMedCentralCrossRef

48.

Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010;20(3):161–8.PubMedPubMedCentralCrossRef

49.

Ulasov I, Yi R, Guo D, Sarvaiya P, Cobbs C. The emerging role of MMP14 in brain tumorigenesis and future therapeutics. Biochimi Biophysic Acta. 2014;1846(1):113–20.

50.

Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 2009;69(4):1517–26.PubMedCrossRef

51.

Markovic DS, Vinnakota K, Chirasani S, Synowitz M, Raguet H, Stock K, et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc Natl Acad Sci U S A. 2009;106(30):12530–5.PubMedPubMedCentralCrossRef

52.

Markovic DS, Vinnakota K, van Rooijen N, Kiwit J, Synowitz M, Glass R, et al. Minocycline reduces glioma expansion and invasion by attenuating microglial MT1-MMP expression. Brain Behav Immun. 2011;25(4):624–8.PubMedCrossRef

53.

Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia. 2011;59(8):1169–80.PubMedCrossRef

54.

McGowan PM, Duffy MJ. Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol. 2008;19(9):1566–72.PubMedCrossRef

55.

Määttä M, Soini Y, Liakka A, Autio-Harmainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res. 2000;6(7):2726–34.PubMed

56.

Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ, van Muijen GN. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol. 2000;191(3):245–56.PubMedCrossRef

57.

Imanishi Y, Fujii M, Tokumaru Y, Tomita T, Kanke M, Kanzaki J, et al. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma. Hum Pathol. 2000;31(8):895–904.PubMedCrossRef

58.

Huang M, Xiong C, Lu W, Zhang R, Zhou M, Huang Q, et al. Dual-modality micro-positron emission tomography/computed tomography and near-infrared fluorescence imaging of EphB4 in orthotopic glioblastoma xenograft models. Mol Imaging Biol. 2014;16(1):74–84.PubMedPubMedCentralCrossRef

59.

Li C, Wang W, Wu Q, Ke S, Houston J, Sevick-Muraca E, et al. Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nucl Med Biol. 2006;33(3):349–58.PubMedCrossRef

60.

Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad ME, et al. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med. 2007;48(9):1501–10.PubMedCrossRef

61.

Kimura RH, Miao Z, Cheng Z, Gambhir SS, Cochran JR. A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects. Bioconjug Chem. 2010;21(3):436–44.PubMedPubMedCentralCrossRef

62.

Olson ES, Jiang T, Aguilera TA, Nguyen QT, Ellies LG, Scadeng M, et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A. 2010;107(9):4311–6.PubMedPubMedCentralCrossRef

63.

Elliott JT, Marra K, Evans LT, Davis SC, Samkoe KS, Feldwisch J, et al. Simultaneous in vivo fluorescent markers for perfusion, protoporphyrin metabolism, and EGFR expression for optically guided identification of orthotopic glioma. Clin Cancer Res. 2017;23(9):2203–12.PubMedCrossRef

64.

Zhu L, Zhang F, Ma Y, Liu G, Kim K, Fang X, et al. In vivo optical imaging of membrane-type matrix metalloproteinase (MT-MMP) activity. Mol Pharm. 2011;8(6):2331–8.PubMedPubMedCentralCrossRef

65.

Gao S, Zhang L, Wang G, Yang K, Chen M, Tian R, et al. Hybrid graphene/Au activatable theranostic agent for multimodalities imaging guided enhanced photothermal therapy. Biomaterials. 2016;79:36–45.PubMedCrossRef

66.

Li D, Zhang J, Chi C, Xiao X, Wang J, Lang L, et al. First-in-human study of PET and optical dual-modality image-guided surgery in glioblastoma using ⁶⁸Ga-IRDye800CW-BBN. Theranostics. 2018;8(9):2508–20.PubMedPubMedCentralCrossRef

67.

Ribeiro de Souza AL, Marra K, Gunn J, Samkoe KS, Hull S, Paulsen KD, et al. Optimizing glioma detection using an EGFR-targeted fluorescent affibody. Photochem Photobiol. 2018;94(6):1167–71.PubMedCrossRef

68.

Acerbi F, Broggi M, Schebesch K-M, Höhne J, Cavallo C, De Laurentis C, et al. Fluorescein-guided surgery for resection of high-grade gliomas: a multicentric prospective phase II study (FLUOGLIO). Clin Cancer Res. 2018;24(1):52–61.PubMedCrossRef

69.

Suchorska B, Jansen NL, Linn J, Kretzschmar H, Janssen H, Eigenbrod S, et al. Biological tumor volume in ¹⁸FET-PET before radiochemotherapy correlates with survival in GBM. Neurology. 2015;84(7):710–9.PubMedCrossRef

70.

Verger A, Filss CP, Lohmann P, Stoffels G, Sabel M, Wittsack HJ, et al. Comparison of ¹⁸F-FET PET and perfusion-weighted MRI for glioma grading: a hybrid PET/MR study. Eur J Nucl Med Mol Imaging. 2017;44(13):2257–65.PubMedCrossRef

71.

Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of ¹⁸F-FET versus ¹⁸F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro-Oncology. 2016;18(3):426–34.PubMedCrossRef

72.

Yoo MY, Paeng JC, Cheon GJ, Lee DS, Chung JK, Kim EE, et al. Prognostic value of metabolic tumor volume on ¹¹C-methionine PET in predicting progression-free survival in high-grade glioma. Nucl Med Mol Imaging. 2015;49(4):291–7.PubMedPubMedCentralCrossRef

73.

Doi Y, Kanagawa M, Maya Y, Tanaka A, Oka S, Nakata N, et al. Evaluation of trans-1-amino-3-¹⁸F-fluorocyclobutanecarboxylic acid accumulation in low-grade glioma in chemically induced rat models: PET and autoradiography compared with morphological images and histopathological findings. Nucl Med Biol. 2015;42(8):664–72.PubMedCrossRef

74.

Yang Y, Hernandez R, Rao J, Yin L, Qu Y, Wu J, et al. Targeting CD146 with a ⁶⁴Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas. Proc Natl Acad Sci U S A. 2015;112(47):E6525–34.PubMedPubMedCentralCrossRef

75.

Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 2006;4(7):437–47.PubMedCrossRef

Titel: Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models
verfasst von: Benjamin B. Kasten
Ke Jiang
Denzel Cole
Aditi Jani
Neha Udayakumar
G. Yancey Gillespie
Guolan Lu
Tingting Dai
Eben L. Rosenthal
James M. Markert
Jianghong Rao
Jason M. Warram
Publikationsdatum: 26.11.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2020
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04607-x

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT

Individualized discrimination of tumor recurrence from radiation necrosis in glioma patients using an integrated radiomics-based model

Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[18F]-fluoroethyl)-l-tyrosine PET

Imaging glioma biology: spatial comparison of amino acid PET, amide proton transfer, and perfusion-weighted MRI in newly diagnosed gliomas

Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome

TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study